Video Experimental Relacionado
Updated: Jun 14, 2026
06:37
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Agentes antiinflamatorios: presente y futuro
1Department of Medicine, University of Colorado, Aurora, 80045, USA. cdinarello@mac.com
Cell
|March 23, 2010
Resumen
La inflamación crónica puede conducir a enfermedades graves. Esta revisión cubre los medicamentos antiinflamatorios actuales y en desarrollo, incluidos los biológicos y las moléculas pequeñas, para controlar estas afecciones.
Área de la Ciencia:
- Inmunología y Farmacología.
- Descubrimiento y Desarrollo de Drogas.
Sus antecedentes:
- La inflamación es una respuesta inmune normal, pero la inflamación crónica conduce a trastornos autoinmunes, neurodegeneración y cáncer.
- Los medicamentos antiinflamatorios existentes como los AINE son efectivos, pero se necesitan nuevas estrategias terapéuticas.
Objetivo del estudio:
- Para revisar el panorama actual de la investigación de fármacos antiinflamatorios.
- Para resaltar nuevos agentes terapéuticos y sus mecanismos de acción.
Principales métodos:
- Revisión de la literatura de los agentes antiinflamatorios existentes y emergentes.
- Discusión de las clases de fármacos que incluyen productos biológicos, pequeñas moléculas, estatinas, inhibidores de HDAC, agonistas de PPAR y ARN pequeños.
Principales resultados:
- Una amplia gama de agentes antiinflamatorios están disponibles y en desarrollo.
- Las nuevas clases de fármacos, como las terapias con anticitocinas y los inhibidores de la quinasa, representan un avance significativo.
Conclusiones:
- La investigación continua en terapias antiinflamatorias es crucial para el manejo de las enfermedades inflamatorias crónicas.
- El desarrollo de nuevos fármacos ofrece vías prometedoras para tratamientos más seguros y efectivos.
Videos de Conceptos Relacionados
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
00:42Cross-reactivity
Overview
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...